A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy

Trial Profile

A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 May 2017

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors JHL Biotech
  • Most Recent Events

    • 29 Mar 2017 Status changed from not yet recruiting to recruiting, according to a JHL Biotech media release.
    • 29 Mar 2017 According to a JHL Biotech media release, the first patient in this trial has been dosed.
    • 08 Jul 2016 Last checked against United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top